# A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07147348/  
OnCo record `nct07147348` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.

## Summary

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07147348 by BioNTech SE, with 375 participants planned, started 2025-08-27 and due to reach its primary completion in 2027-11. Interventions recorded: BNT3212 and Pumitamig.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07147348
- Phase: 1/2
- Setting: A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
- Sponsor: BioNTech SE
- Enrolled: 375

## Sources

- ClinicalTrials.gov NCT07147348: https://clinicaltrials.gov/study/NCT07147348

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct07147348.json